Drug-tolerant persister (DTP) cells drive therapeutic resistance in EGFR-mutant lung adenocarcinoma. Using single-cell RNA sequencing, we identified a clinically significant RGS5+MYL9+ cancer-associated fibroblast (CAF) population that was associated with EGFR tyrosine kinase inhibitor (TKI) resistance and poor prognosis. These CAFs were recruited to DTP niches via CCL11 signaling, and they formed tunneling nanotubes through Miro1/RhoA activation induced by TKI-generated mitochondrial reactive oxygen species. Remarkably, RGS5+MYL9+ CAFs functioned as “metabolic sinks” by accepting tumor-derived damaged mitochondria, thereby promoting DTP survival. Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal–tumor cross-talk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance. Significance: Pharmacological blockade of nanotube-mediated mitochondrial transfer between tumor cells and RGS5+MYL9+ fibroblasts effectively overcome tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer, offering a clinically applicable strategy to enhance EGFR inhibitor efficacy.
Figure S3. RGS5+MYL9+ CAFs Promote EGFR-TKI-Induced DTP. (A-B) ATeam biosensor analysis demonstrates maintained cellular viability (YFP/CFP ratio) in HCC827 (A) and PC9 (B) cells co-cultured with RGS5+MYL9+ CAFs during 2 μM Osimertinib treatment. (C-D) Immunofluorescence staining reveals elevated stemness markers (CD44/CD133) in HCC827 cells protected by RGS5+MYL9+ CAFs under Osimertinib treatment. (E) Western blot shows RGS5+MYL9+ CAF-induced epithelial-mesenchymal transition (EMT) marker expression in Osimertinib treated HCC827 cells. (F) Cell cycle analysis demonstrates RGS5+MYL9+ CAFs-mediated G0/G1 arrest in osimertinib-treated HCC827 and PC9 cells. The primary CAF subsets utilized in this figure were isolated from patients 04 to 06. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data represent mean ± SD (*P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA with Dunnett's test; ns=not significant)
Figure S10. Enhanced stromal-tumor proximity in drug-resistant niches. (A-B) Quantitative analysis of CAF-tumor cell distances in (A) treatment-naïve versus (B) Osimertinib-resistant tissues (corresponding to Figure 1J), demonstrating significantly closer association in resistant tumors. (C-D) Spatial analysis of CAF distribution in (C) untreated versus (D) relapsed tumors (from Figure 2Q), revealing preferential peri-tumoral localization of RGS5+MYL9+ CAFs following therapy. Error bars indicate mean ± SD, with statistical significance marked as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
Figure S2. RGS5+MYL9+ CAFs attenuate EGFR-TKI efficacy in patient-derived organoids. (A) Organoid co-cultures with RGS5+MYL9+ CAFs showed preserved viability (Calcein AM+/PI-) and morphology after 5 μM Osimertinib exposure (days 3-6) compared to RGS5+MYL9+-d CAF controls (B) ATeam biosensor analysis revealed maintained ATP levels (YFP/CFP ratio) in RGS5+MYL9+ CAFs-protected PDOs during treatment, with kinetics showing significant metabolic protection. The primary CAF subsets utilized in this figure were isolated from patients 10 to 12. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars are presented as mean ± SD, with statistical significance indicated as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
Drug-tolerant persister (DTP) cells drive therapeutic resistance in EGFR-mutant lung adenocarcinoma. Using single-cell RNA sequencing, we identified a clinically significant RGS5+MYL9+ cancer-associated fibroblast (CAF) population that was associated with EGFR tyrosine kinase inhibitor (TKI) resistance and poor prognosis. These CAFs were recruited to DTP niches via CCL11 signaling, and they formed tunneling nanotubes through Miro1/RhoA activation induced by TKI-generated mitochondrial reactive oxygen species. Remarkably, RGS5+MYL9+ CAFs functioned as “metabolic sinks” by accepting tumor-derived damaged mitochondria, thereby promoting DTP survival. Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal–tumor cross-talk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance.Significance:Pharmacological blockade of nanotube-mediated mitochondrial transfer between tumor cells and RGS5+MYL9+ fibroblasts effectively overcome tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer, offering a clinically applicable strategy to enhance EGFR inhibitor efficacy.